Use this url to cite publication: https://hdl.handle.net/20.500.12512/243140
Short-term and long-term impacts of ELAV1 inhibitors on pancreatic cancer cell survival in vitro
Type of publication
Tezės kitame recenzuojamame leidinyje / Theses in other peer-reviewed publication (T1e)
Author(s)
| Author | Affiliation |
|---|---|
Dambrauskas, Joris | Vilniaus universitetas |
Title
Short-term and long-term impacts of ELAV1 inhibitors on pancreatic cancer cell survival in vitro
Publisher
Kaunas : Studentų mokslinė draugija
Date Issued
| Date | Start Page | End Page |
|---|---|---|
2024-04-16 | 297 | 298 |
Version
Originalus / Original
Research Area
Medicinos ir sveikatos mokslai / Medical and health sciences (M)
Field of Science
Medicina / Medicine (M001)
Biologija / Biology (N010)
OECD Classification
Medical and Health sciencesClinical medicineGastroenterology and hepatology
Natural sciencesBiological sciencesCell biology, Microbiology
Abstract (en)
Introduction An RNA binding protein, human antigen R (ELAVL1), is a key regulator of a molecular mechanism that is responsible for posttranscriptional gene regulation which is altered in pancreatic ductal adenocarcinoma (PDAC) cells. This, in turn, supports the pro-survival phenotype intrinsic to PDAC cells (1). Therefore, ELAVL1 inhibition could be considered a viable direction for cancer therapeutics (2), however, it is still not clear how different inhibitors affect the cell. [...].
Related publication
International Health Sciences Conference for All (IHSC for All) "Precision Medicine" : Abstract book 2024 : [March 25-26, 2024, Kaunas] / Edited by Ignas Lapeikis, Livija Petrokaitė
Media Type (COAR)
TextConference outputConference proceedingsConference paper
ISSN (of the container)
3030-0711
Coverage Spatial
Lietuva / Lithuania (LT)
Language
Anglų / English (en)
Bibliographic Details
4
Date Reporting
2024